Glaxo in $350mln cancer deal with biotech specialist
British pharmaceuticals giant GlaxoSmithKline has agreed a $350-million deal with Adaptimmune to help develop and sell the biotechnology firm's cancer drugs, the companies said on Monday.
Jun 2, 2014
0
0